A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder
Phase: PHASE3
Conditions: Depressive Disorder, Major
Sponsor: Naurex, Inc, an affiliate of Allergan plc

NCT02932943 
 
Study ID: RAP‐MD‐01 
 
 
 
Title: A Randomized, Double‐blind, Placebo‐controlled, Multicenter Study of Rapastinel 
as Adjunctive Therapy in Major Depressive Disorder 
 
 
 
Protocol Amendment 3 Date: 07 Dec 2018 
 
 
 

Naurex, Inc
1
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
1.0
TITLE PAGE
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as 
Adjunctive Therapy in Major Depressive Disorder
RAP-MD-01
IND # 107,974
Sponsor:
Naurex Inc., an indirect subsidiary 
of Allergan, plc
5 Giralda Farms
Madison, NJ 07940
Original Protocol Date:
28 Apr 2016
Amendment 1:
28 Sep 2016
Amendment 2:
12 Oct 2018
Amendment 3:
07 Dec 2018
Confidentiality Statement
This document is the property of Allergan, plc and may not—in full or part—be passed on, 
reproduced, published, distributed, or submitted to any regulatory authority without the express 
written permission of Allergan, plc.

Naurex, Inc
2
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
2.0
SYNOPSIS AND SCHEDULE OF EVALUATIONS
CLINICAL STUDY SYNOPSIS: Study RAP-MD-01
Study Number
RAP-MD-01
Title of Study
A Randomized, Double-blind, Placebo-controlled, Multicenter 
Study of Rapastinel as Adjunctive Therapy in Major Depressive 
Disorder 
Study Centers (Country)
Approximately 35 study centers (United States)
Development Phase
3
Objective
To evaluate the efficacy, safety, and tolerability of rapastinel 
adjunctive to antidepressant therapy (ADT) in patients with major 
depressive disorder (MDD) who have a partial response to ADT
Methodology
Multicenter, randomized, double-blind, placebo-controlled, parallel-
group, 3-week study in patients with MDD who have a partial 
response to ongoing ADT
Number of Patients
Approximately 460 planned to be enrolled
Diagnosis and Main Criteria for 
Inclusion

Male and female outpatients who are 18 to 65 years of age

Meet Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5) criteria for MDD, with a current major 
depressive episode of at least 8 weeks and not exceeding 
18 months in duration at Visit 1
 
 

Have no more than partial response (< 50% improvement) to 
ongoing treatment with a protocol-allowed ADT
 
 
 
 
 
 
 
 
 
 
 
Test Product, Dosage, and Mode 
of Administration
Rapastinel (450 mg weekly intravenous [IV] administration) 
adjunctive to ongoing ADT, prefilled syringe
Duration of Treatment
Up to 14 days of screening and washout period, followed by a 
3-week double-blind treatment period, followed by a 1-week safety 
follow-up period
Reference Therapy, Dosage, and 
Mode of Administration
Placebo adjunctive to ongoing ADT, weekly IV administration, 
prefilled syringe

Naurex, Inc
3
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
Criteria for Evaluation
Primary Endpoint
Change from baseline in MADRS total score at end of study
Key Secondary Endpoint
Change from baseline in MADRS total score 1 day after the first 
dose of randomized treatment
 
 
 
 
 
 
 
 
 
 
 
.
Safety Measures
Adverse event (AE) recording, clinical laboratory measures, vital 
sign parameters, electrocardiograms (ECGs), and physical 
examinations
 
 
 

Naurex, Inc
4
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
Statistical Methods
The primary efficacy parameter will be the change from baseline in 
MADRS total score at end of study. The primary analysis will be 
performed using a mixed-effects model for repeated measures
(MMRM) with terms for treatment, pooled study center, visit, and
treatment-by-visit interaction as the fixed effects, and baseline 
MADRS total score, baseline MADRS total score-by-visit as 
covariates. The key secondary efficacy parameter, change from 
baseline in MADRS total score 1 day after randomized treatment
will be analyzed using the same MMRM model as was used for the 
primary efficacy parameter. An unstructured covariance matrix will 
be used to model the covariance of within-patient scores. Baseline 
will be defined as the last measurement prior to the first dose of 
double-blind treatment. To control the overall type I error rate for 
both the primary and key secondary endpoint, a sequential testing 
procedure will be implemented.
All safety parameters will be analyzed using descriptive statistics. 
Safety analyses will be based on the Safety Population, defined as 
all randomized patients who receive at least 1 dose of randomized 
treatment. Efficacy analyses will be based on the modified Intent-
to-Treat (mITT) Population, defined as all patients who are
randomized and receive at least 1 dose of treatment and have at 
least 1 postrandomization assessment of the MADRS total score.

Naurex, Inc
5
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
6
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
7
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
3.0
TABLE OF CONTENTS
1.0
TITLE PAGE ..................................................................................................................................................1
2.0
SYNOPSIS AND SCHEDULE OF EVALUATIONS....................................................................................2
3.0
TABLE OF CONTENTS................................................................................................................................7
3.1
LIST OF FIGURES ..........................................................................................................................9
4.0
LIST OF ABBREVIATIONS .......................................................................................................................10
5.0
ETHICAL CONSIDERATIONS ..................................................................................................................12
5.1
Institutional Review Board and Independent Ethics Committee.....................................................12
5.2
Ethical Conduct of the Study ..........................................................................................................12
5.3
Patient Information and Informed Consent.....................................................................................12
6.0
INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE ....................................................13
7.0
INTRODUCTION.........................................................................................................................................14
8.0
STUDY OBJECTIVES.................................................................................................................................18
9.0
INVESTIGATIONAL PLAN .......................................................................................................................20
9.1
Overall Study Design and Plan: Description...................................................................................20
9.1.1
Screening Period...............................................................................................................20
9.1.2
Double-blind Treatment Period ........................................................................................20
9.1.3
Safety Follow-up Period...................................................................................................21
9.2
Discussion of Study Design, Including the Choice of Control Groups...........................................22
9.3
Selection of Study Population.........................................................................................................22
9.3.1
Inclusion Criteria ..............................................................................................................22
9.3.2
Exclusion Criteria.............................................................................................................23
9.3.3
Removal of Patients from Therapy or Assessment...........................................................27
9.3.4
Patient Replacement Procedures.......................................................................................28
9.4
Treatments.......................................................................................................................................28
9.4.1
Background Antidepressant Therapy................................................................................28
9.4.2
Treatments Administered..................................................................................................29
9.4.3
Identity of Investigational Products..................................................................................29
9.4.4
Handling of Investigational Products................................................................................30
9.4.5
Method of Assigning Patients to Treatment Groups.........................................................30
9.4.6
Selection of Dosages in the Study ....................................................................................31
9.4.7
Selection and Timing of Dose for Each Patient................................................................31
Screening Period.............................................................................................31
9.4.7.1
Double-blind Treatment Period ......................................................................31
9.4.7.2
Safety Follow-up Period .................................................................................31
9.4.7.3
9.4.8
Blinding ............................................................................................................................31
9.4.9
Unblinding........................................................................................................................32
9.4.10
Prior and Concomitant Therapy........................................................................................32
9.4.11
Other Restrictions.............................................................................................................34
Alcohol ...........................................................................................................34
9.4.11.1
Contraception..................................................................................................34
9.4.11.2
9.4.12
Monitoring Treatment Compliance...................................................................................34
9.4.13
Treatment After Discontinuation......................................................................................34

Naurex, Inc
8
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
9.5
Efficacy and Safety Variables.........................................................................................................35
9.5.1
Diagnostic and Efficacy Assessments ..............................................................................35
Diagnostic Assessments..................................................................................35
9.5.1.1
Efficacy Assessments......................................................................................35
9.5.1.2
9.5.2
Safety Assessments...........................................................................................................36
Adverse Events ...............................................................................................36
9.5.2.1
Immediate Reporting of Serious Adverse Events and Events of Interest .......40
9.5.2.2
Reporting of Pregnancies Occurring During the Study ..................................40
9.5.2.3
9.6
Data Quality Assurance ..................................................................................................................55
9.6.1
Data Monitoring................................................................................................................55
9.6.2
Data Recording and Documentation.................................................................................55
9.7
Statistical Methods and Determination of Sample Size..................................................................56
9.7.1
Analysis Populations ........................................................................................................56
Enrolled Population ........................................................................................56
9.7.1.1
Safety Population............................................................................................56
9.7.1.2
Modified Intent-to-Treat Population...............................................................56
9.7.1.3
9.7.2
Patient Disposition............................................................................................................57
9.7.3
Demographics and Other Baseline Characteristics...........................................................57
9.7.4
Extent of Exposure and Treatment Compliance ...............................................................57
Extent of Exposure..........................................................................................57
9.7.4.1
Measurement of Treatment Compliance.........................................................58
9.7.4.2
9.7.5
Efficacy Analyses.............................................................................................................58
Primary Efficacy Parameter............................................................................58
9.7.5.1
Key Secondary Efficacy Parameter ................................................................59
9.7.5.2
9
9.7.6
Safety Analyses ................................................................................................................61
Adverse Events ...............................................................................................61
9.7.6.1

Naurex, Inc
9
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
9.7.8
Interim Analysis................................................................................................................64
9.7.9
Determination of Sample Size ..........................................................................................64
9.7.10
Computer Methods ...........................................................................................................65
9.8
Data and Safety Monitoring Board .................................................................................................65
9.9
Changes in the Conduct of the Study or Planned Analyses ............................................................65
9.10
Protocol Deviations.........................................................................................................................66
10.0
STUDY SPONSORSHIP..............................................................................................................................67
10.1
Study Termination...........................................................................................................................67
10.2
Reporting and Publication...............................................................................................................67
11.0
INVESTIGATOR OBLIGATIONS..............................................................................................................68
11.1
Documentation................................................................................................................................68
11.2
Performance ....................................................................................................................................68
11.3
Use of Investigational Materials .....................................................................................................69
11.4
Case Report Forms..........................................................................................................................69
11.5
Retention and Review of Records...................................................................................................69
11.6
Patient Confidentiality ....................................................................................................................69
12.0
INVESTIGATOR’S STATEMENT .............................................................................................................70
13.0
APPENDICES...............................................................................................................................................71
Appendix I.
Elements of Informed Consent .........................................................................................71
Appendix II.
Contact Information..........................................................................................................73
Appendix V.
Montgomery-Asberg Depression Rating Scale.................................................................82
14.0
LITERATURE CITED................................................................................................................................105
3.1
LIST OF FIGURES

Naurex, Inc
10
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
4.0
LIST OF ABBREVIATIONS
Abbreviation/Term
Definition
ADT
antidepressant therapy
AE
adverse event
ALT
alanine aminotransferase 
AST
aspartate aminotransferase
ATRQ 
Antidepressant Treatment Response Questionnaire
BMI
body mass index
BP
blood pressure
CFR
Code of Federal Regulations
CI
confidence interval
DSM-5
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
DSST
Digit Symbol Substitution Test
DxV
Diagnostic Validation Questionnaire
ECG
electrocardiogram, electrocardiographic
eCRF
electronic case report form
ECT
electroconvulsive therapy
EDC
electronic data capture
 
ET
early termination
FDA
Food and Drug Administration
FR
Federal Register
GCP
good clinical practice
HIPAA
Health Insurance Portability and Accountability Act of 1996
ICF
informed consent form
ICH
International Conference on Harmonisation 
IND
Investigational New Drug (application)
IP
investigational product
IRB
Institutional Review Board
IV
intravenous
IWRS
interactive web response system
MADRS
Montgomery-Åsberg Depression Rating Scale
MDD
major depressive disorder
mITT
modified Intent-to-Treat
MMRM
mixed-effects model for repeated measures
NMDAR 
N-methyl-D-aspartate receptor
PCS
potentially clinically significant
PID
patient identification
QTc
QT interval corrected for heart rate
QTcB
QT interval corrected for heart rate using the Bazett formula (QTcB = QT/[RR]½)
QTcF
QT interval corrected for heart rate using the Fridericia formula (QTcF = QT/[RR]⅓)
SAE
serious adverse event
SAP
Statistical Analysis Plan
 
SD
standard deviation

Naurex, Inc
11
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
Abbreviation/Term
Definition
SDMT
Symbol Digit Modalities Test
SNRI
selective serotonin and norepinephrine reuptake inhibitor
SSRI
selective serotonin reuptake inhibitor
TEAE
treatment-emergent adverse event
UDS
urine drug screen
ULN
upper limit of normal

Naurex, Inc
12
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
5.0
ETHICAL CONSIDERATIONS
5.1
INSTITUTIONAL REVIEW BOARD AND INDEPENDENT ETHICS 
COMMITTEE
Approval by the Institutional Review Board (IRB) before the start of the study will be the 
responsibility of the Investigator. A copy of the approval letter will be supplied to the Sponsor, 
along with a roster of IRB members or the US Department of Health and Human Services 
general assurance number. During the course of the study, the Investigator will provide timely 
and accurate reports to the IRB on the progress of the study, at intervals not exceeding 1 year (or 
as appropriate), and will notify the IRB of serious adverse events (SAEs) or other significant 
safety findings. The study protocol, informed consent form (ICF), information sheet 
advertisements, and amendments (if any) will be approved by the IRBs at the study centers in 
conformance with the US CFR, 
Title 21, Part 56.
5.2
ETHICAL CONDUCT OF THE STUDY
This clinical study will be conducted in accordance with the ethical principles that have their 
origins in the Declaration of Helsinki.
This clinical study will comply with the ICH Guidance on General Considerations for Clinical 
Trials (ICH-E8; 62 FR 66113, 17 Dec 1997) and GCP (ICH-E6; 62 FR 25692, 09 May 1997), as 
well as Part 312 of the US CFR.
5.3
PATIENT INFORMATION AND INFORMED CONSENT
After being given an explanation of the study and before participating in any study procedures, 
each patient must provide written informed consent in compliance with 
21 CFR, Parts 50 and 312 and give HIPAA authorization. 
Each patient will read and sign an ICF and/or other authorization form as per local regulations; 
each patient will be made aware that he or she may withdraw from the study at any time.
The ICF contains all the elements of informed consent listed in Appendix I of this protocol. 
Signed copies of the ICF and the HIPAA or other locally applicable form will be given to the 
patient, and both documents will be placed in the Investigator’s study files.

Naurex, Inc
13
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
6.0
INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE
This study will be performed at approximately 35 study centers in the United States.
The Investigator is responsible for ensuring that the investigation is conducted according to the 
signed Investigator statement, the investigational plan, GCP guidelines, and applicable 
regulations; for protecting the rights, safety, and welfare of patients under the Investigator’s care; 
and for the control of investigational products under investigation. An investigator shall obtain 
the informed consent for each patient prior to the patient enrolling in the study and/or prior to 
participating in any study-related activity. 
The Investigator at each study center must meet his or her obligations to the patients, ethics 
committee, Sponsor, and regulatory authorities by maintaining oversight and control of the 
study’s conduct and the study staff. It is the responsibility of the Investigator to ensure that any 
and all delegated duties be assigned to qualified staff by education, experience, and licensure (in 
accordance with local regulations) and that the Investigator oversight is documented and 
assessment of staff capabilities and performance is consistent with the study investigational plan. 
The Investigator at each study center will be responsible for the management of the study, 
including maintaining the study file and the patient records, corresponding with the IRB, and 
completing the electronic case report forms (eCRFs).

Naurex, Inc
14
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
7.0
INTRODUCTION
Disease Burden of Major Depressive Disorder
Major depressive disorder (MDD) is a highly disabling, serious condition which is associated 
with significant morbidity and mortality. MDD manifests as a major depressive episode (which 
may be singular or recurrent) in which the affected individual experiences 1) depressed mood, or
2) loss of interest or pleasure (as well as other symptoms) for most of the day, nearly every day,
for at least 2 weeks. MDD affects approximately 14.8 million American adults, or about 6.7% of 
the US population 18 years of age and older, in a given year (Kessler et al, 2005). Worldwide, 
about 15% of the adult population is at lifetime risk of developing MDD (Kessler et al, 1994).
Depression may cause serious, long-lasting symptoms and often disrupts a person’s ability to 
perform routine tasks. In 2000, unipolar depressive disorders were by far the leading cause 
(11.9%) of worldwide years of life lived with disability 
(World Health Organization, 2001), and the total economic burden of treating depression in the 
United States was $83.1 billion, with workplace costs, including missed days and lack of 
productivity due to illness, accounting for most of the total economic burden (62%). Other 
economic burdens in 2000 included $26.1 billion (31%) for treatment costs and $5.4 billion (7%) 
for suicide-related costs (Greenberg et al, 2003). 
MDD is a leading cause of disability in the United States (Murray et al, 2013). Moreover, MDD 
is known to be a significant risk factor for suicide and ischemic heart disease, as it accounted for 
16 million of the disability adjusted life years (DALYs) associated with suicide and 4 million of 
the DALYs associated with ischemic heart disease. Research has shown that untreated 
depression has both a functional (social and work role) as well as a neuroanatomical 
(hippocampal shrinkage) effect on the patient (Videbech and Ravnkilde, 2004). Given the 
disease burden and link to suicidality as well as increased mortality with other comorbid 
conditions, MDD is a serious and life-threatening condition which is a leading cause of disability 
in the world.
Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Norepinephrine 
Reuptake Inhibitors in Major Depressive Disorder
Selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and norepinephrine 
reuptake inhibitors (SNRIs) currently represent the first line of treatment of depression in the 
United States. Unfortunately, a large number of patients do not experience therapeutic benefit 
from these first-line agents (Rosenzweig-Lipson et al, 2007). Lack of sufficient response to 
adequate treatment remains a critical problem in the management of patients with MDD. Up to 
two-thirds of patients treated with first-line antidepressant monotherapy do not reach full 
remission, and as many as a third become treatment resistant (Fava and Davidson, 1996; 
Trivedi et al, 2006). Not achieving remission has been shown to be predictive of poorer 
psychosocial functioning, higher rates of relapse, and higher rates of rehospitalization 
(McIntyre and O’Donovan, 2004). 

Naurex, Inc
15
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
The results of the STAR*D study suggest that with successive failures of treatment, patients are 
less and less likely to respond to subsequent treatment, and those who do respond are more likely 
to relapse (Rush et al, 2006). Present strategies available to treat patients who do not respond to 
first-line antidepressant monotherapy include switching of antidepressant (either within or 
between classes); combination therapy in which multiple antidepressants are used 
simultaneously; augmentation of ongoing antidepressant monotherapy with adjunctive use of 
drugs such as mood stabilizers or atypical antipsychotics (Boland and Keller, 2006); and 
nonpharmacologic treatments including psychotherapy and phototherapy, vagus nerve 
stimulation, transcranial magnetic stimulation, and electroconvulsive therapy (ECT). Clearly, 
there remains a critically important unmet medical need for this patient population.
Existing antidepressants have a number of limitations, leading to considerable unmet medical 
need in the effective treatment of MDD, with up to 50% of patients with MDD having an 
inadequate response or failing current antidepressant therapy (ADT). Currently available first-
line antidepressants (SSRIs, SNRIs) typically take 3 to 4 weeks or more of continuous daily 
dosing to relieve symptoms of MDD and are associated with side effects related to their 
pharmacological mechanisms of action (sexual dysfunction, weight gain, jitteriness, sleep 
disturbances), which are further associated with poor patient compliance (Masand 2003, Ashton 
et al, 2005). Patients often experience undesirable side effects before they experience an 
improvement in depressive symptoms, which could lead to premature discontinuation of therapy. 
Taken together, these factors define significant areas for improvement of ADT. 
Patients vary greatly in their response to antidepressants and it is not possible to reliably predict 
whether an individual patient will respond to a given antidepressant. This leads to clinicians 
often using a trial-and-error approach to identify an effective antidepressant. Due to the gradual 
development of the full therapeutic effect of currently available antidepressants, each 
antidepressant needs to be administered for 4 weeks or longer in order to determine the 
individual therapeutic benefit, making the process of finding an effective antidepressant a 
lengthy process for patients who are often severely depressed and at a high risk for suicide. 
Clearly a drug that could induce a rapid antidepressant effect would represent a major 
advancement for these patients.
Atypical Antipsychotics as Adjunctive Therapy in Major Depressive Disorder
The available treatments for adjunctive therapy in MDD also have substantial safety and efficacy 
limitations. The drugs currently approved for use as adjunctive therapy to antidepressants for the 
treatment of MDD—namely, the atypical antipsychotics Abilify® (aripiprazole), Seroquel XR® 
(quetiapine fumarate), and Rexulti® (brexpiprazole)—are associated with significant adverse 
reactions, as well as a number of serious warnings and precautions. Originally developed for the 
treatment of psychotic disorders, these drugs share a number of clinically relevant adverse effects 
based on their mechanisms of action. 

Naurex, Inc
16
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
As all current antipsychotic agents modulate central dopaminergic systems, they all carry a risk 
of extrapyramidal symptoms such as muscular rigidity, acute dystonia, as well as akathisia, 
which is a particularly relevant adverse event (AE) that complicates clinical management in a 
significant number of treated individuals, as high as 45% (Sachdev, 1995). In addition, these 
compounds are associated with a risk of neuroleptic malignant syndrome and tardive dyskinesia. 
Depending on their individual pharmacological profile, antipsychotics also carry a risk for
metabolic changes including hyperglycemia/diabetes mellitus, dyslipidemia and body weight 
gain; blood dyskrasias such as leucopenia, neutropenia, and agranulocytosis; orthostatic 
hypotension; cognitive and motor impairment; cataracts; and insomnia (Abilify, 2014; Seroquel, 
2013; 
Rexulti, 2015). The range of clinically relevant side effects with antipsychotics has to be 
balanced carefully against the potential for therapeutic benefits in patients with major depression. 
In this context it is important to highlight that for the approved atypical antipsychotics the full 
therapeutic benefit required several weeks of daily adjunctive dosing to become apparent, and in 
many subjects, adverse effects occurred substantially earlier than the mood-alleviating effects of 
these drugs. 
Furthermore, the drugs currently approved for adjunctive treatment of MDD also have limited 
efficacy. The pivotal studies for Abilify, the atypical antipsychotic most commonly used for 
adjunctive treatment of MDD, showed a delayed onset of effect (1-2 weeks), a modest magnitude 
of effect (effect sizes were 0.35-0.39 after 6 weeks of repeat dosing) and modest rates of 
response and remission after 6 weeks of repeat dosing (response rates were 32-34% and 
remission rates were 25-26%) (Berman et al, 2007; Marcus et al, 2008). 
Clearly, there is a substantial need for the development of novel treatments with a better 
safety/tolerability profile and a faster onset of full therapeutic benefit. Rapastinel has initially 
shown substantially improved safety/tolerability as well as promising efficacy, in both speed of 
onset and overall magnitude, for adjunctive therapy in MDD. 
Rapastinel as a Novel Approach to Major Depressive Disorder Treatment
The mechanism of action of rapastinel is entirely different from that of atypical antipsychotics.
Rapastinel is an N-methyl-D-aspartate receptor (NMDAR) modulator with a novel and complex 
pharmacological mechanism of action, acting as a nonselective agent at NR2 subunits and 
displaying properties as a functional partial agonist in a number of pharmacological assays. 
Rapastinel has demonstrated antidepressant properties in relevant animal models, displays 
cognitive enhancing properties in treated animals, and facilitates hippocampal long-term 
potentiation (LTP) of synaptic transmission in preclinical models. In contrast to ketamine, no 
signal of abuse liability was detected in informative animal models. 

Naurex, Inc
17
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
Rapastinel is available as an intravenous (IV) formulation only. In 2 Phase 2 clinical studies in 
patients with MDD, single IV doses of rapastinel 5 mg/kg and 10 mg/kg have been shown to 
produce marked antidepressant effects within 1 day that lasted for approximately 1 week or 
longer in responding patients. These antidepressant effects are very similar to ketamine’s effects 
when administered at a low dose as an infusion. In a systematic review and meta-analysis of 
ketamine and other NMDAR antagonists in the treatment of major depression, a single infusion 
of ketamine produced a rapid, yet transient antidepressant effect, accompanied by brief 
psychotomimetic and dissociative effects (Newport et al, 2015). 
The available Phase 1 and 2 data demonstrated a favorable safety and tolerability profile of 
rapastinel. In contrast to ketamine, rapastinel has not shown a high likelihood to induce 
psychotomimetic or dissociative effects in humans so far. 
The purpose of this study is to prospectively confirm that rapastinel, when administered as an 
adjunctive treatment at a dose of 450 mg as a short IV infusion in patients with MDD, is 
significantly superior to placebo in rapidly reducing depressive symptoms. Furthermore, the 
safety and tolerability of rapastinel will be investigated. The study is intended to support an 
application for regulatory approval of rapastinel as adjunctive treatment for MDD.

Naurex, Inc
18
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
8.0
STUDY OBJECTIVES
The objectives of this study are to evaluate the efficacy, safety, and tolerability of rapastinel 
adjunctive to ongoing ADT in patients with MDD who have a partial response to ADT.
Efficacy Objectives

Primary efficacy objective: To evaluate the efficacy of rapastinel (450 mg IV) versus placebo 
in the treatment of MDD as an adjunct to ongoing ADT, as measured by the change from 
baseline to end of study in the Montgomery-Åsberg Depression Rating Scale (MADRS) total 
score.

Key secondary efficacy objective: To evaluate the efficacy of rapastinel (450 mg IV) versus
placebo in the treatment of MDD as an adjunct to ongoing ADT, as measured by the change 
from baseline in the MADRS total score 1 day after first dose of treatment.
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc
19
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc
20
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
9.0
INVESTIGATIONAL PLAN
9.1
OVERALL STUDY DESIGN AND PLAN: DESCRIPTION
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-
week study in patients with MDD who have a partial response to ADT. The study will include a 
total of 12 visits and will be approximately 4 to 6 weeks in duration (Figure 9.1.3–1): 

Up to 2-week screening period 

3-week double-blind treatment period 

1-week safety follow-up period (for patients who do not enter the RAP-MD-04 maintenance 
study)
9.1.1
Screening Period
After providing written consent, patients will enter a screening period of up to 14 days. The 
screening/washout period will be up to 2 weeks prior to Visit 2. Screening procedures may be 
conducted on up to 2 separate dates where necessary to accommodate patient and study center
schedule; however, every effort should be made to conduct all procedures as early as possible in 
the screening period and the rater-administered MADRS and computer-administered MADRS 
must be collected on the same date. Patients will not receive any investigational product (IP)
during the screening period but must continue their background ADT at the same dose. Patients 
meeting the eligibility criteria at the end of Visit 2 (Baseline) will be assigned a treatment by the 
interactive web response system (IWRS) and enter the double-blind treatment period.
9.1.2
Double-blind Treatment Period
Approximately 460 patients are planned for enrollment in the double-blind treatment period (230
patients each in the rapastinel 450 mg and placebo groups). Patients will be randomized in a ratio 
of 1:1 to 1 of 2 treatment groups: rapastinel 450 mg IV weekly or placebo IV weekly (both 
adjunctive to ongoing ADT). 
During the double-blind treatment period, patients will have 3 study visits per week. The visits 
will occur in the following pattern: treatment day, 1 day following the treatment day, 4 days 
following the treatment day, and 7 days following the treatment day (which is the next treatment 
day). If necessary, study visits may be conducted up to 2 days before or after the scheduled visits 
with the exception of visits that are 24 hours apart (eg, Visits 2 and 3 must be conducted 1 day 
apart; similarly, Visits 5 and 6 as well as Visits 8 and 9 must be conducted 1 day apart). All 
patients who receive IP must complete Visit 11. Upon completion of the double-blind treatment 
period, patients are eligible to enter the RAP-MD-04 maintenance study. Patients who do not 
enter RAP-MD-04 will enter a 1-week safety follow-up period.

Naurex, Inc
21
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
9.1.3
Safety Follow-up Period
Patients who do not enter the RAP-MD-04 maintenance study upon completing the double-blind 
treatment period and patients who prematurely discontinue from the study before completing 3 
weeks of double-blind treatment should enter the 1-week safety follow-up period. 
Additional follow-up visits may be scheduled within 30 days, if necessary for safety reasons.
A schematic of the study design is presented in Figure 9.1.3–1. The Schedule of Evaluations is 
provided in Section 2.0 and detailed descriptions of each study visit can be found in 
Section 9.5.6.

Naurex, Inc
22
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
9.2
DISCUSSION OF STUDY DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUPS
This multicenter, randomized, placebo-controlled, parallel-group study with a 3-week double-
blind treatment period, was designed based on prior studies that established rapastinel efficacy 
and safety in adult patients with MDD. In this study, investigators will enroll patients 18 through 
65 years of age who meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition (DSM-5) criteria for MDD (American Psychiatric Association, 2013). The MDD 
diagnosis will be confirmed using the Modified Structured Clinical Interview for Diagnostic 
Statistic Manual of Mental Health Disorders, Fifth Edition (SCID). The symptoms and severity 
of MDD will be assessed using the MADRS (Section 9.5.1.2.1). 
Study centers will have experience with the study population and will be encouraged to apply 
available guidelines to minimize patient risk or distress. 
Dose selection information is presented in Section 9.4.6. The planned dosing regimen is based on 
experience from previous rapastinel studies. 
A placebo treatment group is included in the study to comply with worldwide regulatory 
preferences (Laughren, 2001; Gispen-de Wied et al, 2012), since placebo-controlled superiority 
trials have been shown to be conducive to higher quality studies and to provide more reliable 
outcomes (Feifel, 2008; Laughren, 2001; Gispen-de Wied et al, 2012). Additionally, from a 
scientific point of view, randomized double-blind comparisons versus placebo are needed to 
permit adequate evaluation of efficacy. Comparison to a placebo treatment is also of value for 
distinguishing disease manifestations from adverse reactions to the IP (EMA guidance, 2013). 
The use of placebo in place of the standard therapy should not cause irreversible health problems 
or extreme suffering (depression is recognized by the FDA as a condition in which there is 
substantial improvement and variability in placebo groups) (FDA Guidance for Industry: E10, 
May 2001). 
In Study RAP-MD-01, safety and efficacy assessments are included at every visit to determine 
adequacy of response, safety, and tolerability. In the event of insufficient therapeutic response or 
worsening of the patient’s initial condition, the IP should be discontinued and an alternative 
treatment will then be allowed (Section 9.4.13). An independent Data and Safety Monitoring 
Board (DSMB) will evaluate safety data during the study (Section 9.8).
9.3
SELECTION OF STUDY POPULATION
9.3.1
Inclusion Criteria
To be eligible to participate in the study, patients must meet the following criteria:
1. Written informed consent, obtained from the patient before the initiation of any 
study-specific procedures (Section 5.3) 
2. Male or female outpatients, 18 to 65 years of age

Naurex, Inc
23
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
3. Meet DSM-5 criteria for MDD (based on confirmation from the modified SCID, with a 
current major depressive episode of at least 8 weeks and not exceeding 18 months in duration 
at Visit 1
 
 
6. Have no more than partial response (< 50% improvement) to ongoing treatment with a 
protocol-allowed ADT
 
 
 
 
 
 
8. If female of childbearing potential, have a negative serum β-human chorionic gonadotropin 
(β-hCG) pregnancy test
9.3.2
Exclusion Criteria
Patients who meet any of the following criteria will not be eligible to participate in the study:
Exclusion criteria to be assessed at Screening (Visit 1)
Psychiatric and Treatment-Related Criteria
1. DSM-5–based diagnosis of any disorder other than MDD that was the primary focus of 
treatment within 6 months before Visit 1. Comorbid generalized anxiety disorder, social 
anxiety disorder, or specific phobias are acceptable provided they play a secondary role in 
the balance of symptoms and are not the primary driver of treatment decisions.
2. Lifetime history of meeting DSM-5 criteria for:
a.
Schizophrenia spectrum or other psychotic disorder

Naurex, Inc
24
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
b. Bipolar or related disorder
c.
Major neurocognitive disorder 
d. Neurodevelopmental disorder of greater than mild severity or of a severity 
that impacts the patient’s ability to consent, follow study directions, or 
otherwise safely participate in the study
e.
Dissociative disorder
f.
Posttraumatic stress disorder
g. MDD with psychotic features
 
 
 
 
 
 
 
 

Naurex, Inc
25
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
9. Suicide risk, as determined by meeting any of the following criteria:
 
 
 
 
 
 
 

Naurex, Inc
26
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc
27
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
9.3.3
Removal of Patients from Therapy or Assessment
A premature discontinuation will occur when a patient who signed the ICF ceases participation 
in the study, regardless of circumstances, before the completion of the study visits and 
procedures. Patients can be prematurely discontinued from the study after careful consideration 
for one of the following reasons:

Screen failure (failure to meet inclusion/exclusion criteria)

Pregnancy

Withdrawal of consent 

AE
o
Any patient may be withdrawn due to AE at the discretion of the Investigator
o
Any patient who meets any of the following criteria at any point during the study 
must be withdrawn from participation, due to AEs related to suicide:
a) A suicide attempt
 
In the event that a patient is withdrawn for a suicide-related AE, the patient should be referred 
for additional treatment or hospitalization, as clinically indicated, in addition to withdrawing the 
patient from the study.

Lack of efficacy

Protocol violation

Noncompliance with IP

Noncompliance with ADT

Lost to follow-up 

Study terminated by Sponsor

Study center terminated by Sponsor

Naurex, Inc
28
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Other 
All randomized patients who prematurely discontinue from the study, regardless of cause, should 
be seen for a final assessment at an Early Termination (ET) Visit. A final assessment will be 
defined as completion of the evaluations scheduled for all patients at Visit 11. All patients 
discontinuing the study prematurely should enter the 1-week safety follow-up period.
Patients who discontinue from the study and do not return to the study center for final 
assessments must be requested in writing to return to the study center for a final assessment. A 
copy of the letter, together with the source documentation, will be kept in the Investigator’s files. 
The reason for premature discontinuation from the study will be recorded on the Study 
Termination Page of the eCRF. Study center staff will be contacted by the Sponsor after each 
premature discontinuation to ensure proper characterization of the reason for discontinuation is 
captured.
9.3.4
Patient Replacement Procedures
Patients in this study who prematurely discontinue treatment will not be replaced.
9.4
TREATMENTS
Patients meeting the eligibility criteria at the end of Visit 2 (Baseline) will be randomized in 
double-blind fashion to 1 of 2 treatment groups: placebo or rapastinel 450 mg. 
9.4.1
Background Antidepressant Therapy
Patients must enter the study while having no more than partial response 
(< 50% improvement) to ongoing treatment with a protocol-allowed ADT
 
 
 
 
 
 
 
 
 
Upon entry into the study at Screening (Visit 1), the dosage of the ADT must be held constant at 
a dose allowed in the respective label through Visit 11/ET. If a patient experiences an AE, 
intercurrent illness, or symptoms of intolerance, he or she will be permitted to stop taking the 
ADT for a maximum of 3 consecutive days at the discretion of the Investigator. No other 
alterations in the ADT dose regimen are allowed. If an ADT dose change is required during the 
study, the patient should be discontinued from the study. 
Background ADT medication compliance will also be closely monitored. Patients should be 
questioned to determine if there were any missed doses or changes in dose at 
Visits 2, 5, 8, and 11. Every effort should be made to have patients bring their background ADT 
to Visits 5, 8, and 11 for verification of patient-reported compliance by pill count (to the extent
possible).

Naurex, Inc
29
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
9.4.2
Treatments Administered
The IP will only be administered to eligible patients by a medically qualified person as per the 
local state regulations. The range of persons who can administer an IV can be a physician, a 
physician assistant, nurse, or nurse practitioner, etc, depending on the local and/or state law.
IP should be administered after all efficacy and safety assessments with the exception of the 
postdose assessments described below. IP will be administered in a “slow bolus” injection to 
each study patient in an upper extremity vein within approximately 
1 to 2 minutes. 
During IP administration and until completion of postadministration assessments a licensed 
physician must be immediately available and in close proximity to the patient(s) to attend to 
medical emergencies. The study center must have the capabilities, in accordance with the 
applicable country, local, and/or state regulations and standard of care, to resuscitate a patient in 
the event of a medical emergency.
The patient should not be discharged from the study center until the following are completed:

Postadministration vital sign measures (approximately 15 minutes after administration)

Patient is clinically assessed and determined to not be at increased risk of suicidality in 
the opinion of the Investigator (or medically qualified subinvestigator)

Patient is assessed for mental status and is determined to be free of perceptual 
disturbances or other conditions that would deem them not ready for discharge from the 
study center, in the opinion of the Investigator (or medically qualified subinvestigator)

A physician licensed in the state (Investigator or subinvestigator) determines that they are 
medically able to leave the study center and provides written signoff not less than 15 
minutes following administration (see IV Administration and Discharge Notes document 
in Program Reference Manual)
9.4.3
Identity of Investigational Products
Rapastinel 450 mg IV Prefilled Syringes: 
 
Placebo rapastinel IV Prefilled Syringes: prefilled single-dose syringes for injection containing 3 
mL of normal saline.

Naurex, Inc
30
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
The study center personnel will complete the kit label and attach the tear-off portion to the 
source documents. 
The prefilled syringe will be labeled with the protocol number and kit number. The study center 
personnel will write the PID number on the prefilled syringe associated with the kit mentioned 
above. The prefilled syringe will not have a tear off and will remain on the prefilled syringe.
9.4.4
Handling of Investigational Products
The IP must be stored in a secure area and administered only to patients entered into the clinical 
study, at no cost to the patient, in accordance with the conditions specified in this protocol.
 
.
 
Study centers must report any temperature excursions as described in the 
Study Reference Manual or contact the Sponsor or its designee for further instructions. 
At the end of the study, all IP must be accounted for. In addition, at the end of the study, all 
unused IP should be returned to the Sponsor or the local distributor at the address provided in the 
Study Reference Manual.
9.4.5
Method of Assigning Patients to Treatment Groups
After a patient signs the ICF at Screening (Visit 1), study personnel will register the patient in the 
IWRS, and the system will assign the patient a sequential PID.
 
 
his PID 
number will be used to identify the patient throughout the study (ie, at all periods of the study).
The IP will be labeled with medication kit numbers. The IWRS will provide the study center
with the specific medication kit number(s) for each randomized patient at the time of 
randomization. Study centers will dispense IP according to the IWRS instructions. Study centers
will also log onto the IWRS at subsequent visits to obtain a study medication kit number for 
dispensing the IP. Study centers will receive the IWRS confirmation notifications for each 
transaction. All notifications are to be maintained with the study source documents.

Naurex, Inc
31
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
9.4.6
Selection of Dosages in the Study
The dose of rapastinel in this study was selected based on 2 Phase 2 clinical studies in patients 
with MDD, in which single IV doses of rapastinel 5 mg/kg and 10 mg/kg were shown to produce 
marked antidepressant effects within 1 day that lasted approximately 1 week or longer in 
responding patients.
A 450-mg unit dose is expected to be appropriate for most patients as this represents a dose of 
4.5 mg/kg in a 100 kg patient and a dose of 9 mg/kg in a 50 kg patient.
9.4.7
Selection and Timing of Dose for Each Patient
The IP will be administered IV using the assigned single-use prefilled syringes at Visits 2, 5, and 
8.
Screening Period
9.4.7.1
At Screening (Visit 1) after written consent is obtained, patients enter a screening period of up to 
14 days. No IP is administered during the screening period; however, patients must continue 
their background ADT at a stable dose.
Double-blind Treatment Period
9.4.7.2
Patients who meet all eligibility criteria at Screening (Visit 1) and who continue to meet all the 
eligibility criteria for participation in the study at the Baseline Visit (Visit 2) will be assigned an 
IP kit number via IWRS at Baseline (Visit 2). Patients will receive the first dose of IP that day. 
The IP kit numbers will also be assigned by IWRS at subsequent treatment visits (ie, Visits 5 and 
8).
Patients will receive either rapastinel 450 mg or placebo from a prefilled single-dose syringe at 
Visits 2, 5, and 8. 
Safety Follow-up Period 
9.4.7.3
Patients who complete 3 weeks of randomized treatment are eligible to enter the RAP-MD-04 
maintenance study. If they do not enter RAP-MD-04, they should enter the safety follow-up 
period. Patients who discontinue the study prematurely should enter the safety follow-up period. 
No IP is administered during the safety follow-up period and patients’ background ADT may be 
modified as deemed appropriate by the Investigator.
9.4.8
Blinding
A list of patient randomization codes will be generated by Statistical Programming and 
implemented by the IWRS vendor (an electronic version will be stored on a secure server). This 
list will identify each patient by randomization number and include the patient’s corresponding 
treatment assignment.

Naurex, Inc
32
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
All study treatments will be provided in identical syringes and cartons to maintain masking of 
the study.
9.4.9
Unblinding
Any unblinding at the study center level should be done only in an emergency that requires 
identification of the IP for the medical management of the patient. The Investigator must notify 
the Study Physician immediately (refer to Appendix II) and a full written explanation must be 
provided if the blind is broken. Before IP is unblinded, every attempt should be made to discuss 
the case with the Study Physician. Breaking the code at the study center will immediately 
disqualify the patient from further participation in the study.
Treatment codes may be broken by Global Drug Safety for regulatory reporting purposes. In 
such cases, the study staff will be kept blinded and the patient will not need to be disqualified 
from the study.
For IWRS Unblinding
In an emergency, the Investigator can obtain the treatment assignment of any patient at his or her 
study center through the IWRS. The Investigator will access the IWRS to break the blind and 
record the unblinding in the eCRF.
9.4.10
Prior and Concomitant Therapy
A list of example medications that are allowed and not allowed as concomitant medications for 
either episodic or chronic use is provided in Appendix III. Medication history (psychotropic 
medication history during the previous 5 years and all other medications during the past 12 
months) will be recorded at Screening (Visit 1) in the eCRF. Thereafter, any changes in 
concomitant medications or any new medications added will be recorded in the eCRF.
 
 
 
 
 
 
 

Naurex, Inc
33
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Zolpidem extended rele
 
 
 
 
 
 
 
 
 
 

Naurex, Inc
34
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
9.4.11
Other Restrictions
Alcohol 
9.4.11.1
It is recommended that patients abstain from alcohol consumption during the study.
Contraception
9.4.11.2
For purposes of this study, females will be considered of childbearing potential unless they are 
naturally postmenopausal or permanently sterilized (ie, hysterectomy). Natural menopause is 
defined as the permanent cessation of menstrual periods, determined retrospectively after a 
woman has experienced 12 months of amenorrhea without any other obvious pathological or 
physiological cause. 
For women of childbearing potential and male partners of childbearing potential who may 
participate in the study, the following methods of contraception, if properly used, are generally 
considered reliable: hormonal contraceptives (ie, oral, patch, injection, implant), male condom 
with intravaginal spermicide, diaphragm or cervical cap with spermicide, vaginal contraceptive 
ring, intrauterine device, surgical sterilization (bilateral tubal ligation, bilateral salpingectomy), 
vasectomized partner, or sexual abstinence.
The Investigator and each patient will determine the appropriate method of contraception for the 
patient during the participation in the study.
See Section 9.5.2.3 for pregnancy reporting procedures.
9.4.12
Monitoring Treatment Compliance
IP compliance during any period will be closely monitored by capturing the date and time of 
each injection of IP. If a scheduled injection does not occur, the Sponsor must be notified and the 
reason captured in the eCRF.
Background ADT compliance will also be closely monitored. Patients should be questioned to 
determine if there were any missed doses or changes in dose at 
Visits 2, 5, 8, and 11. Every effort should be made to have patients bring their background ADT 
to Visits 5, 8, and 11 for verification of patient-reported compliance by pill count (to the extent 
possible). Missed doses or other changes in the dose of ADT and the reason should be captured 
in the eCRF.
9.4.13
Treatment After Discontinuation
Patients whose MDD symptoms worsen or are determined by the Investigator not to be 
adequately controlled prior to completing the double-blind treatment period will be allowed to 
discontinue the study and start appropriate treatment at the Investigator’s discretion. This new 
treatment will not be provided by the Sponsor. Patients who initiate a new treatment must be 
discontinued from the study.

Naurex, Inc
35
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
9.5
EFFICACY AND SAFETY VARIABLES
9.5.1
Diagnostic and Efficacy Assessments
Diagnostic Assessments
9.5.1.1
The SCID will be administered during the screening interviews by a psychiatrist, doctoral level 
clinical psychologist, or other clinician who has extensive professional training and experience in 
the diagnosis of mental illness and who meets the training requirements and qualifications 
standards set by the Sponsor and rater training vendor.
Patients will complete a computer-administered Diagnostic Validation (DxV) assessment at the 
Screening visit prior to the rater-administered SCID, on a tablet computer provided to the study 
center. The DxV will collect data about the patients’ history relative to lifelong history of MDD. 
The patient’s diagnostic information, based on the responses to the computerized interview, will 
be reviewed by the independent clinical reviewers team appointed by the Sponsor, and any 
uncertainty raised by the patient’s responses on the diagnostic interview will be discussed with 
the Investigator/study center clinician in order to establish confidence in the diagnosis. Patients 
for whom diagnostic agreement between the Investigator/study center clinician and the rater 
vendor clinician cannot be reached, may not be appropriate for study participation.
 
 
 
 
 
Efficacy Assessments
9.5.1.2
The efficacy assessments (MADRS 
will be administered by a psychiatrist, doctoral 
level clinical psychologist, or other clinician who has extensive professional training and 
experience in the diagnosis of mental illness and who meets the training requirements and 
qualifications standards set by the Sponsor and rater training vendor.
9.5.1.2.1
The Montgomery-Åsberg Depression Rating Scale
The MADRS (Montgomery and Åsberg, 1979) is a clinician-rated scale. The MADRS will be 
used to assess depressive symptomatology. Patients are rated on 10 items to assess feelings of 
sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty 
concentrating, and lack of interest. Each item will be scored on a 
7-point scale. A score of 0 indicates the absence of symptoms, and a score of 6 indicates 
symptoms of maximum severity. 

Naurex, Inc
36
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
A qualified rater (ie, who meets the training requirements and qualifications set by the rater 
training vendor) at each investigational center will conduct the MADRS assessment. The rater-
administered MADRS will be used for analyses. In addition to MADRS administration by a 
qualified rater, each patient will complete an interactive, 
computer-administered MADRS interview on the dedicated study device. Data from the 
computer-administered interview will be compared with data derived from the 
rater-administered interview on an ongoing basis as part of a remote quality assurance program 
conducted by an independent vendor appointed by the Sponsor. 
At each visit with a MADRS assessment, the rater-administered MADRS interview will be audio 
recorded. The computer-administered interview will involve a series of probe and follow-up 
questions with multiple-choice response options. At the Screening Visit, the computer 
administered MADRS will be conducted prior to the rater-administered MADRS. At all other 
visits, the rater-administered MADRS will be conducted first.
 
 
 
 
 
9.5.2
Safety Assessments
Patients must be evaluated by a physician or an appropriately trained health care professional at 
every visit and the evaluation must be documented. The procedures discussed below will be 
completed at the designated visits.
Adverse Events
9.5.2.1
An AE is any untoward medical occurrence in a patient or clinical investigation patient 
administered a pharmaceutical product and which does not necessarily have to have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding, for example), symptom, or disease temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product (ICH-E2A).
For the purposes of the study center’s data collection responsibilities, any untoward event that 
was reported from the time the patient signed the ICF until 30 days after the final protocol-
defined study visit or the last known dose of IP (if the final visit does not occur) is to be 
considered an AE.
Examples of AEs are as follows:

Changes in the general condition of the patient

Subjective symptoms offered by or elicited from the patient

Naurex, Inc
37
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Objective signs observed by the Investigator or other study center personnel

All diseases that occur after signing informed consent, including any change in severity or 
frequency of pre-existing disease

All clinically relevant abnormalities in laboratory values or clinically relevant physical 
findings that occur during the study schedule
Please note that medical procedures scheduled prior to consenting but occurring during the study 
should not be captured as AEs, but should be listed in the medical history if related to a pre-
existing condition.
9.5.2.1.1
Causality Assessment
For each AE, the Investigator must provide an assessment of causal relationship to the IP. The 
causality assessment must be recorded on the appropriate AE reporting page of the patient’s 
eCRF. Causal relationship must be assessed by answering the following question:
Is there a reasonable possibility the IP caused the event?
Yes:
There is evidence to suggest a causal relationship between the IP and AE, ie: 

There is a reasonable temporal relationship between the IP and the event, and/or 

The event is unlikely to be attributed to underlying/concurrent disease or other 
factors, and/or

Positive dechallenge and/or rechallenge exist
No:
There is no evidence to suggest a causal relationship between the IP and AE, ie:

There is no reasonable temporal relationship between the IP and the event, or

The patient did not take the IP, or

The event is likely to be attributed to underlying/concurrent disease or other factors, 
or

The event is commonly occurring in the (study) population independent of IP
exposure
9.5.2.1.2
Severity Assessment
The Investigator will provide an assessment of the severity of each AE by recording a severity 
rating on the appropriate AE reporting page of the patient’s eCRF. Severity, which is a 
description of the intensity of manifestation of the AE, is distinct from seriousness, which 
implies a patient outcome or AE-required treatment measure associated with a threat to life or 
functionality (Section 9.5.2.1.3). Severity will be assessed according to the following scale:

Naurex, Inc
38
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
Mild:
A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.
Moderate:
A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, causing 
discomfort, but poses no significant or permanent risk of harm to the research 
participant.
Severe:
A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.
9.5.2.1.3
Serious Adverse Events
An SAE is any untoward medical occurrence that at any dose:

Results in death

Is life threatening

Requires inpatient hospitalization or prolongation of existing hospitalization

Results in persistent or significant disability/incapacity, or

Is a congenital anomaly/birth defect
Important medical events that may not result in death, be life threatening, or require 
hospitalization may be considered serious when, based on appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
or convulsions that do not result in patient hospitalization, or the development of IP dependency 
or drug abuse.
Emergency room visits that do not result in hospitalization should be evaluated for one of the 
other serious outcomes to determine whether they qualify as SAEs.
Preplanned hospitalizations (eg, elective procedures for pre-existing conditions that did not 
worsen, such as cosmetic surgery and hysterectomy) are excluded from SAE reporting.
9.5.2.1.4
Reporting Adverse Events and Serious Adverse Events
At each visit, patients are to be queried regarding any AEs or SAEs that have occurred since the 
previous visit. Patients will be asked to volunteer information with a nonleading question such 
as, “How do you feel since your last visit?” Study center personnel will record all pertinent 
information in the patient’s eCRF. 
All AEs must be recorded on the appropriate AE reporting page of the patient’s eCRF whether or 
not they are considered causally related to the IP.

Naurex, Inc
39
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
For every AE, the Investigator must:

Provide an assessment of the seriousness of the event (ie, is it an SAE?), as well as the 
severity and casual relationship

Document all actions taken with regard to the IP

Detail any other treatment measures taken for the AE

Document the outcome of the AE
In addition, patients are to be reminded, as described in the ICF and in accordance with Section 
9.5.2.1, to notify study center personnel of any AEs occurring during the 30-day poststudy 
period. Any AEs reported by the patient (or patient representative) during this period are to be 
recorded in original source documents. AEs are also to be recorded in the eCRF if at least one of 
the following conditions is met: 1) the event meets the criteria for an SAE (see Sections 9.5.2.1.3
and 9.5.2.1.4), and/or 2) the event is judged by the Investigator to be potentially causally related 
to IP.
Any AEs that are ongoing at the time of the final protocol-defined study visit will be followed 
until the condition returns to prestudy status, has resolved or stabilized, or can be explained as 
being unrelated to the IP. If a follow-up visit is deemed necessary for appropriate safety 
surveillance, it will take place within 30 days of the final protocol-defined study visit.

Naurex, Inc
40
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
Immediate Reporting of Serious Adverse Events and Events of Interest
9.5.2.2
The Sponsor is required to inform worldwide regulatory authorities of SAEs that meet specific 
criteria. Therefore, the Sponsor must be notified immediately regarding any SAE that occurs 
after informed consent is obtained.
Within 24 hours of learning of any AE that meets one of the criteria for an SAE, the study center
personnel must report the event to Global Drug Safety on the SAE Form for Clinical Trials. The
Study Physician may also be notified by telephone.
If, during follow-up, any nonserious AE worsens and eventually meets the criteria for an SAE, 
that AE should be recorded as a new SAE. 
The study center must transmit the SAE Form for Clinical Trials to the SAE fax number shown 
below. Even if an initial report is made by telephone, the SAE Form for Clinical Trials 
completed with all available details must still be faxed within 24 hours of knowledge of the event 
at the study center.
Supplemental information should be submitted as soon as available and may include laboratory 
results, radiology reports, progress notes, hospital admission and emergency room notes, holding 
and observation notes, discharge summaries, autopsy reports, and death certificates.
The Investigator is expected to take all therapeutic measures necessary for resolution of the SAE. 
Any medications or procedures necessary for treatment of the SAE must be recorded on the 
appropriate pages of the patient’s eCRF. All SAEs are to be followed by the study staff until 
resolution or until the SAE is deemed stable. The Sponsor may contact the study center to solicit 
additional information or follow up on the event.
Fax the SAE Form for Clinical Trials to the Sponsor.
Reporting of Pregnancies Occurring During the Study
9.5.2.3
Study center personnel must report every pregnancy from the time the patient signs the ICF until 
30 days after the last dose of IP. Within 24 hours of learning of the pregnancy, the study center
personnel must report the event to Global Drug Safety on the Clinical Trial Pregnancy Form and 
fax it to the SAE/Pregnancy fax number provided in Section 9.5.2.2, even if no AE has occurred. 
Pregnancies in female partners of male patients occurring during the time frame described above 
must also be reported. 

Naurex, Inc
41
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
Any pregnancy of a patient treated with IP (or in female partners of male patients occurring 
during the timeframe described above) must be followed to term and the outcome reported by 
completing a follow-up Clinical Trial Pregnancy Form. If the pregnancy is associated with an 
SAE (eg, if the mother is hospitalized for hemorrhage), a separate SAE Form for Clinical Trials 
must be filed as described in Section 9.5.2.2, with the appropriate serious criterion (eg, 
hospitalization) indicated in addition to the pregnancy form.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc
42
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc
43
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc
44
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc
45
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc
46
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.5.6
Schedule of Assessments
The schedule of study procedures and assessments is tabulated by visit in the Schedule of 
Evaluations in Section 2.0. The descriptions of the procedures to be performed at each visit are 
provided in the following sections.
Upon providing written informed consent, patients enter a screening period of up to 14 days.
Following the screening period, patients enter the 3-week, double-blind treatment period. During 
the double-blind treatment period, patients have 3 study visits per week. The visits occur in the 
following pattern: treatment day, 1 day following the treatment day, 4 days following the 
treatment day, and 7 days following the treatment day (which is the next treatment day). If 
necessary, study visits may be conducted up to 2 days before or after the scheduled visits with 
the exception of visits that are 24 hours apart (ie, Visits 2 and 3 must be conducted 1 day apart; 
similarly, Visits 5 and 6 as well as Visits 8 and 9 must be conducted 1 day apart). Upon 
completion of the double-blind treatment period, patients are eligible to enter the RAP-MD-04 
maintenance study or enter a 1-week safety follow-up period.

Naurex, Inc
47
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 

Naurex, Inc
48
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 

Naurex, Inc
49
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 

Naurex, Inc
50
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 

Naurex, Inc
51
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 

Naurex, Inc
52
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 

Naurex, Inc
53
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 

Naurex, Inc
54
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 

Naurex, Inc
55
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
Unscheduled Visits
9.5.6.13
Unscheduled visits can be performed if safety concerns arise and at the discretion of the 
Investigator. Additional examinations may be performed as necessary to ensure the safety and 
well-being of the patients during the study.
9.6
DATA QUALITY ASSURANCE
9.6.1
Data Monitoring
Before any patient enters the study, a representative of the Sponsor will meet with the 
Investigator and the study center staff to review the procedures to be followed during the study. 
Electronic data capture (EDC) functionality training is provided via computer-based training to 
train investigators and authorized designees on recording the data in the eCRFs using the EDC 
system. After the first patient is enrolled, the Sponsor representative, a Regional Site Manager or 
designee, will periodically monitor the progress of the study by conducting on-site visits. This 
Regional Site Manager or designee will review query statuses remotely, possibly warranting 
more frequent communication and/or study center visits with the Investigator and the study 
center staff. The Investigator will make available to the Regional Site Manager or designee 
source documents (written notes and electronic medical records, if used), signed consent forms, 
and all other study-related documents. The Investigator and the study center staff will be 
responsible for data entry of patient data into the eCRFs via the EDC system, resolving data 
queries generated via the EDC system and providing missing or corrected data. The Investigator 
or designee will be responsible for approving all changes performed on the data, and endorsing 
the patient data within the EDC system. This approval method will include applying an 
electronic signature linked to a uniquely assigned username and password that together will 
represent a traditional handwritten signature used in the past.
9.6.2
Data Recording and Documentation
Data collection will involve the use of the EDC system, to which only authorized personnel will 
have access. Patient’s data are to be entered into the EDC system by the Investigator or designee 
using their assigned EDC user account. After data entry into the EDC system by the Investigator 
or designee, a combination of manual and programmatic edit checks will be used to review the 
data for completeness, logic, and adherence to study protocol. As a result of these edit checks, 
data monitoring, and reviews, queries may be electronically issued to the study center and should 
be answered electronically via the EDC system.

Naurex, Inc
56
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
Each query will carry identifying information (assigned username, date, and time) to assist the 
Sponsor and the Investigator on the origin of the data clarification request and the response 
provided by the Investigator. All data changes made to the patient’s data via a data query will be 
approved by the Investigator prior to final database lock.
After all data have been reviewed and all issues have been resolved, the database will be locked.
All data collected in the context of this study will be stored and evaluated per regulatory 
requirements and applicable guidance for electronic records. Also, data will be stored and 
evaluated in such a way as to guarantee patient confidentiality in accordance with the legal 
stipulations applying to confidentiality of data. Study records (eg, copies of eCRFs, laboratory 
reports, regulatory documents) will be retained at the study center, along with adequate source 
documentation, according to FDA and ICH requirements. All study records must be available for 
inspection by the Sponsor, its authorized representatives, the FDA, or other health authorities.
 
 
 Source documents will be used at the study centers and 
may include a patient’s medical record, hospital charts, clinic charts, the Investigator’s patient 
study files, as well as the results of diagnostic tests such as laboratory tests, ECGs, etc. 
A centralized clinical laboratory will be used for the analysis of all blood samples. Additional 
information on the collection and handling of samples is detailed in the Lab Procedure Manual.
9.7
STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE
9.7.1
Analysis Populations
Three populations will be considered in the statistical analysis of the study, as specified in the 
following subsections.
Enrolled Population
9.7.1.1
The Enrolled Population will consist of all patients who sign informed consent, receive a patient 
identification number (PID) number, and enter into screening.
Safety Population
9.7.1.2
The Safety Population will consist of all patients who receive at least 1 dose of randomized IP.
Modified Intent-to-Treat Population
9.7.1.3
The modified Intent-to-Treat (mITT) Population will consist of all patients who are randomized, 
receive at least 1 dose of IP and have at least 1 postbaseline assessment of the MADRS total 
score. 

Naurex, Inc
57
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
9.7.2
Patient Disposition
The number and percentage of patients in the Enrolled, Safety, and mITT populations will be 
summarized by treatment group and study center.
Screen-failure patients (ie, patients screened but not included in the Enrolled Population) and the 
associated reasons for failure will be tabulated overall for all screened patients. 
The number and percentage of patients in the mITT Population who complete the double-blind 
treatment period and of patients who prematurely discontinue during the same period will be 
presented for each treatment group and pooled across treatment groups. The reasons for 
premature discontinuation during the double-blind treatment period as recorded on the 
disposition pages of the eCRFs will be summarized by treatment group for the mITT Population.
9.7.3
Demographics and Other Baseline Characteristics
Demographic parameters (eg, age, race, ethnicity, sex, weight, height, body mass index) and 
other baseline characteristics will be summarized by treatment group for the Safety and mITT 
populations. 
9.7.4
Extent of Exposure and Treatment Compliance
Extent of Exposure
9.7.4.1
Patients in the Safety Population will be categorized by the number of IP doses received. The 
number and percentage of patients in each category will be summarized by treatment group. 
Prior medication is defined as any medication taken before the date of the first dose of 
randomized IP. Concomitant medication is defined as any medication taken on or after the date 
of the first dose of IP. 
Both prior and concomitant medication use will be summarized by the number and proportion of 
patients in each treatment group receiving each medication within each therapeutic class for the 
Safety Population. Multiple medication use by a patient will only be counted once.
IV administration notes including site reaction at placement of IV, reaction to adhesive, infusion 
interruption, failure of administration device, increase in suicidality based on clinical evaluation, 
and perceptual disturbance based on mental status assessment are collected. For each item, the 
number and percentage of patients who had a ‘yes’ response will be summarized by treatment 
group and visit for the Safety Population. The number and percentage of patients taking each 
qualifying ADT will be summarized by treatment group for the mITT Population. Mean daily 
dose for each qualifying ADT will be summarized using descriptive statistics (number of 
patients, mean, standard deviation [SD], median, Q1, Q3, minimum, and maximum) by treatment 
group for the mITT Population.

Naurex, Inc
58
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
Measurement of Treatment Compliance
9.7.4.2
Dosing compliance for the background ADT during a specified period is defined as the total 
daily dose administered to a patient during that period divided by the total daily dose prescribed 
during the same period multiplied by 100, as captured in the eCRF. Descriptive statistics for 
ADT compliance will be presented for each ADT and overall by treatment group for the mITT
Population.
9.7.5
Efficacy Analyses
All efficacy analyses will be based on the mITT Population, unless stated otherwise. The 
baseline for each specific efficacy endpoint is defined as the last measurement prior to the first 
dose of randomized treatment. All statistical hypothesis tests will be performed at the 2-sided 5% 
significance level for main effects. All confidence intervals (CIs) will be 2-sided 95% CIs, unless 
stated otherwise.
For efficacy analyses in which study center is a factor, a small center will be defined as a center 
with < 2 patients in ≥ 1 treatment group in the mITT Population. Small centers will be pooled to 
form pseudo-centers so that each treatment group includes ≥ 2 mITT patients within the center. 
Details of the pooling algorithm will be provided in the Statistical Analysis Plan (SAP).
Primary Efficacy Parameter
9.7.5.1
The primary efficacy parameter will be the change from baseline in MADRS total score at end of 
study. The primary analysis will be performed using a mixed-effects model for repeated 
measures (MMRM) with treatment group, pooled study center, visit and randomized treatment-
by-visit interaction as the fixed effects, and baseline MARDS total score and baseline MADRS 
total score-by-visit interaction as covariates. An unstructured covariance matrix will be used to 
model the covariance of within-patient scores. The Kenward-Roger approximation will be used 
to estimate the denominator degrees of freedom (Kenward et al, 1997; Kenward et al, 2003). The 
treatment difference for rapastinel versus placebo will be estimated and reported along with the 
corresponding 95% CI and nominal p-value.
In the case that the MMRM model with unstructured covariance fails to converge with the 
default algorithm, then the Fisher scoring algorithm will be used to provide better initial values 
of the covariance parameters; if the model still does not converge, a simplified model without 
term for study center will be used to find the initial values of the covariance parameters. In the 
rare event that the model still does not converge after using those initial values, simplified 
covariance structures will be used to fit the model in the following order: (1) ante-dependence, 
(2) heterogeneous autoregressive, 
(3) Toeplitz, and (4) compound symmetry.

Naurex, Inc
59
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
To assess the robustness of the primary MMRM results to the possible violation of the missing-
at-random assumption, a sensitivity analysis using a pattern-mixture model based on non-future 
dependent missing value restrictions (Kenward et al, 2003) will be performed. The pattern for the 
pattern-mixture model will be defined by the patient’s last visit with observed value. The 
observed MADRS total score at a visit is assumed to have a linear relationship with the patient’s 
prior measurements. The missing values will be imputed under the assumption that the 
distribution of the missing observations differs from the observed only by a shift parameter value 
Δ. The dataset with missing values will be analyzed using the same model as the primary 
analysis for between-treatment group comparisons at the end of the treatment. The imputation of 
missing values and the analysis will be performed multiple times and the inference of this 
sensitivity analysis will be based on the combined estimates using the standard multiple 
imputation technique. The values of Δ will be selected as 0 to 8.
Key Secondary Efficacy Parameter
9.7.5.2
The key secondary efficacy parameter will be the change from baseline to 1 day after the first dose 
of treatment in MADRS total score. This parameter will be analyzed using the same MMRM as 
will be used for the primary efficacy parameter. The treatment difference for rapastinel versus 
placebo will be estimated and reported along with the corresponding 95% CI and nominal p-
value.
A sequential testing procedure will be used to control the overall type I error rate at 
5% for the primary and secondary efficacy parameters. 
 
 
 
 
 
 

Naurex, Inc
60
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc
61
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
Adverse Events
9.7.6.1
All AEs will be coded by system organ class and preferred term using the Medical Dictionary for 
Regulatory Activities.
An AE (classified by preferred term) will be considered a treatment-emergent adverse event 
(TEAE) if it was not present before the first dose of IP or was present before the date of the first 
dose of IP and increased in severity after the first dose of IP. An AE that becomes serious after 
the date of first dose of IP will also be considered as a TEAE. If more than 1 AE is reported 
before the first dose of IP and coded to the same preferred term, the AE with the greatest severity 
will be used for comparison with the AEs occurring during the double-blind treatment period that 
were also coded to that preferred term. An AE that occurs more than 30 days after the date of the 
last dose of IP will not be considered as a TEAE.
The number and percentage of patients reporting TEAEs in each treatment group will be 
tabulated by system organ class and preferred term and further categorized by severity and causal 
relationship to the IP. If more than 1 AE is coded to the same preferred term for the same patient, 
the patient will be counted only once for that preferred term using the greatest severity and 
strictest causality for the summarization by severity and causal relationship.
A serious adverse event (SAE) that occurred between the date of the first dose of IP and 30 days 
after the date of the last dose of IP, inclusive, will be considered 
a treatment-emergent SAE (TESAE). The number and percentage of patients who have 
on-therapy TESAEs will be summarized by preferred term and treatment group. In addition, the 
incidence of on-therapy SAEs that lead to death will be summarized separately by preferred term 
for each treatment group.
Overall summaries of AEs will be provided on a per-patient basis for categories of all TEAEs, 
treatment-related TEAEs, TESAEs, and TEAEs leading to study discontinuation.
 
 

Naurex, Inc
62
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc
63
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Naurex, Inc
64
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.7.8
Interim Analysis
At the time of preparation for Protocol Amendment 2, a blinded interim analysis was 
performed as part of data quality review as the study was progressing. In this review, it 
was observed that the SD for the primary and secondary endpoints were substantially 
lower than the originally assumed values for sample size calculations. The observed SDs in 
the blinded reviews of this study and other ongoing acute studies at the same time (RAP-
MD-02 and RAP-MD-03) were taken into consideration for revising the estimate of the 
sample size as proposed in the next section (Section 9.7.9 Determination of Sample Size).
9.7.9
Determination of Sample Size
The originally proposed primary efficacy variable is the change from baseline in the MADRS 
total score at 1 day after the first dose of treatment. The study was planned to randomize 700 
patients assuming standard deviation (SD) of 10 points, which provides 99% power to detect a 
difference of 3.25 points in MADRS total score between rapastinel 450 mg and placebo at a 2-
sided significance level of 0.05.   

Naurex, Inc
65
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
While the study was ongoing, the primary efficacy variable was revised to be the change 
from baseline in MADRS score at the last visit, Day 21, as recommended by the FDA, 
EMA, and PDMA, and included in Amendment 2 of the protocol. At the same time of 
Amendment 2, a blinded data review was conducted for Studies RAP-MD-01, RAP-MD-02, 
and RAP-MD-03. The pooled SD for the 3 studies were 7.4, 8.0, and 8.7, respectively, all 
smaller than the originally assumed 10 points. Sample size was re-calculated using 8.7 as the 
common SD. The calculation used MMRM model with simulations; it also assumed 
correlation of 0.5 between the repeated measures and an overall discontinuation rate of 15%. 
To have 90% power, the total sample size required is 360 patients. However, the study had 
already enrolled more than 440 patients with less than 5% of overall discontinuation rate, 
surpassing the re-estimated sample size of 360 patients. The study enrollment was halted as 
soon as operationally feasible. The final sample size is approximately 460 patients (230 
patients per treatment group).
9.7.10
Computer Methods
Statistical analyses will be performed using version 9.3 (or newer) of SAS.
9.8
DATA AND SAFETY MONITORING BOARD
The study will be conducted under the supervision of an independent DSMB to be chartered to 
review safety data at predetermined points during the study. The DSMB may also decide to meet 
and review safety data at other timepoints should it be deemed necessary. The DSMB is 
responsible for the ongoing review of safety data in the clinical study and for making 
recommendations concerning the continuation, modification, and termination of the study 
(FDA Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data 
Monitoring Committees, March 2006).
All analyses that are required to support the DSMB will be performed by an independent
unblinded statistician not otherwise involved in the study. Details of the DSMB membership, 
meeting schedule, and data review and analysis will be documented in the DSMB Charter.
9.9
CHANGES IN THE CONDUCT OF THE STUDY OR PLANNED 
ANALYSES
Any amendment to this protocol will be provided to the Investigator in writing by the Sponsor. 
No protocol amendment may be implemented (with the exceptions noted below) before it has 
been approved by the IRB, and the signature page, signed by the Investigator, has been received 
by the Sponsor. If the protocol is amended to eliminate or reduce the risk to patients, the 
amendment may be implemented before IRB review and approval. However, the IRB must be 
informed in writing of such an amendment, and approval must be obtained within reasonable 
time limits. 

Naurex, Inc
66
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
9.10
PROTOCOL DEVIATIONS
A protocol deviation is any change, divergence, or departure from the study design or procedures 
that is under the Investigator’s responsibility and oversight (as defined by regulations) without 
prior written IRB approval or favorable opinion of an appropriate amendment and that does not 
have a major impact on the patient’s rights, safety, or 
well-being, or on the integrity and authenticity of the study data. Deviations may include, but are 
not limited to, departure from inclusion/exclusion criteria, dosing, duration of treatment, failure 
to perform the required assessments at specified timepoints, scheduling of visits not in 
accordance with specifications, or patient safety. Deviating from the protocol is permitted only if 
absolutely necessary for the safety or clinical management of the patients and must immediately 
be reported to the Sponsor.
A significant protocol deviation is a form of protocol deviation that has a major impact on the 
patient’s rights, safety, or well-being, or on the integrity and authenticity of the study data. The 
IRB must be notified within the time period dictated by the IRB associated with this study. 

Naurex, Inc
67
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
10.0
STUDY SPONSORSHIP
This study is sponsored by Naurex, Inc., an affiliate of Allergan, plc. 
10.1
STUDY TERMINATION
The Sponsor reserves the right to terminate the study in its entirety or at a specific study center
before study completion. 
10.2
REPORTING AND PUBLICATION
All data generated in this study are the property of the Sponsor. An integrated clinical and 
statistical report will be prepared at the completion of the study.
Publication of the results by the Investigator will be subject to mutual agreement between the 
Investigator and the Sponsor and will follow the Sponsor’s Standard Operating Procedure on 
publications.

Naurex, Inc
68
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
11.0
INVESTIGATOR OBLIGATIONS
11.1
DOCUMENTATION
The Investigator must provide the following to the Sponsor before the start of the study:

A completed and signed Form FDA 1572. If, during the course of the study, any changes are 
made that are not reflected on Form FDA 1572, a new Form FDA 1572 must be completed 
and returned to the Sponsor for submission to the FDA.

A fully executed contract

The curricula vitae for the Investigator and all subinvestigators listed on Form FDA 1572, 
including a copy of each physician’s license

A copy of the original IRB approval for conducting the study. If the study is ongoing, 
renewals must be submitted at yearly intervals. All subsequent modifications must be 
submitted and approved by the IRB, as stated in Section 5.1.

A copy of the IRB-approved ICF

A copy of the HIPAA authorization form, or other local privacy applicable forms

A list of the IRB members or the US Department of Health and Human Services general 
assurance number

A copy of the laboratory certifications and reference ranges

The Investigator’s Statement page in this protocol, signed and dated by the Investigator

Financial disclosure agreement completed and signed by the Investigator and all 
subinvestigators listed on Form FDA 1572. The Investigator and all subinvestigators will 
provide an updated financial disclosure agreement to the Sponsor 1 year after the completion 
of the study.
11.2
PERFORMANCE
The Investigator must demonstrate reasonable efforts to obtain qualified patients for the study.

Naurex, Inc
69
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
11.3
USE OF INVESTIGATIONAL MATERIALS
The Investigator will acknowledge that the IP supplies are investigational and as such must be 
used strictly in accordance with the protocol and only under the supervision of the Investigator or 
subinvestigators listed on Form FDA 1572. The IP must be stored in a secured place and must be 
locked. At study initiation, a representative from the Sponsor will inventory the IP at the study 
center. The Investigator must maintain adequate records documenting the receipt and disposition 
of all study supplies. The Sponsor will supply forms on which to record the date the IP was 
received and a dispensing record in which to record each patient’s use. All unused IP must be 
returned to the Sponsor. 
11.4
CASE REPORT FORMS
All patient data relating to the study will be recorded on eCRFs to be provided by the Sponsor
through the EDC system. The Investigator is responsible for verifying that all data entries in the 
eCRFs are accurate and correct by electronically signing the completed eCRF casebook 
submitted to the Sponsor. The Investigator must maintain and retain accurate documentation that 
supports the information entered into the EDC system for source document verification and 
possible regulatory inspection.
11.5
RETENTION AND REVIEW OF RECORDS
Records and documents pertaining to the conduct of this study, including eCRFs, source 
documents, consent forms, regulatory documents, clinical laboratory results, calibration logs, or 
reports (including, but not limited to, all local and central laboratory results and ECG reports), 
and medication inventory records in all formats (including, but not limited to, written, electronic, 
magnetic, and optical records, and scans, x-rays, and ECGs) must be retained by the Investigator
for a period of at least 15 years after study completion unless local regulations or institutional 
policies require a longer retention period or otherwise notified in writing by the Sponsor. 
No study records shall be destroyed without notifying the Sponsor and providing the Sponsor the 
opportunity to arrange long-term storage for such study records or authorizing in writing the 
destruction of records after the required retention period.
The Investigator must permit access to any documentation relating to the study upon request of 
the Sponsor or applicable regulatory authorities. If the Investigator for the study retires, 
relocates, or for other reasons withdraws from the responsibility of keeping the study records, 
custody must be transferred to a suitable alternate custodian employee of the institution or to a 
suitably qualified and responsible third party. The Sponsor must be notified in writing of the 
name and address of the new custodian in advance of the transfer.
11.6
PATIENT CONFIDENTIALITY
All patient records will only be identified by initials and PID number. Patients’ names are not to 
be transmitted to the Sponsor. The Investigator will keep a master patient list on which the PID
number and the full name, address, and telephone number of each patient are listed.

Naurex, Inc
70
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
12.0
INVESTIGATOR’S STATEMENT
I agree to conduct the study in accordance with this protocol (RAP-MD-01, Amendment 3, dated
07 Dec 2018) and with all applicable government regulations and good clinical practice 
guidance.
_______________________________________
_____/_____/______
Investigator’s Signature
Date
_______________________________________
Investigator’s Name

Naurex, Inc
71
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
13.0
APPENDICES
APPENDIX I.
ELEMENTS OF INFORMED CONSENT
Procedures will comply with 21 CFR, Parts 50 and 312. Signed informed consent will be 
obtained from each patient participating in a clinical research study. This consent must include 
the following items:

A statement that the study involves research and an explanation of the purposes of the 
research; a description of the procedures to be followed and the identification of any 
procedures that are experimental; and the expected duration of the patient’s participation

A description of any reasonably foreseeable risks or discomforts to the patient

A description of any benefits to the patient or to others that may reasonably be expected from 
the research. If the patient is to be paid for participating in the study, the consent form must 
state the amount that he/she will receive and the schedule of payment (to ensure neither 
coercion nor undue influence)

A disclosure of appropriate alternative procedures or courses of treatment, if any, that might 
be advantageous to the patient

A statement describing the extent, if any, to which confidentiality of records identifying the 
patient will be maintained and noting the possibility that the FDA, the Sponsor, the IRB, or 
an authorized contract research organization may inspect the records

For research involving more than minimal risk, an explanation of whether any medical 
treatment is available if injury occurs and, if so, what it consists of or where further 
information may be obtained

An explanation of whom to contact, including the relevant telephone number, for answers to 
pertinent questions about the research and the research patient’s rights and whom to contact 
in the event of a research-related injury to the patient. (Note: In some cases, it may be 
necessary to identify a person other than the Investigator as the contact. The guidance of the 
IRB may be required)

A statement that participation is voluntary, that refusal to participate will involve no penalty 
or loss of benefits to which the patient is otherwise entitled, and that the patient may 
discontinue participation at any time without penalty or loss of benefits to which the patient
is otherwise entitled

A statement that the particular treatment or procedures may involve risks to the patient (or to 
the embryo or fetus if the patient is, or may become, pregnant) that are at present 
unforeseeable

The expected circumstances for which the patient’s participation may be terminated by the 
Investigator without regard to the patient’s consent

Naurex, Inc
72
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Any additional costs to the patient that may result from participation in the research

The consequences of a patient’s decision to withdraw from the research and procedures for 
an orderly termination of the patient’s participation

A statement that significant new findings developed during the course of the research that 
may relate to the patient’s willingness to continue participation will be provided to the patient

The approximate number of patients involved in the study

A statement of permission, providing consent for the patient to participate
(eg, “I agree to participate . . .”)

A place for the patient’s signature and date of signing the ICF

A statement indicating that information about this study has been, or will be, entered into a 
databank that is publicly accessible at www.ClinicalTrials.gov.
A copy of the signed consent form must be given to the patient.

Naurex, Inc
73
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
APPENDIX II.
CONTACT INFORMATION 
Contact information for the Sponsor personnel is maintained in the Study Reference Manual.

Naurex, Inc
74
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
75
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
76
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
77
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
78
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
79
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
80
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
81
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
82
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
APPENDIX V.
MONTGOMERY-ASBERG DEPRESSION RATING SCALE
1. APPARENT SADNESS—Representing despondency, gloom and despair (more than just 
ordinary transient low spirits) reflected in speech, facial expression, and posture. Rate by 
depth and inability to brighten up.
0
No sadness.
1
2
Looks dispirited but does brighten up without difficulty.
3
4
Appears sad and unhappy most of the time.
5
6
Looks miserable all the time. Extremely despondent.
2. REPORTED SADNESS—Representing reports of depressed mood, regardless of whether it 
is reflected in appearance or not. Includes low spirits, despondency, or the feeling of being 
beyond help and without hope. Rate according to intensity, duration and the extent to which 
the mood is reported to be influenced by events.
0
Occasional sadness in keeping with the circumstances.
1
2
Sad or low but brightens up without difficulty.
3
4
Pervasive feelings of sadness or gloominess. The mood is still influenced by external 
circumstances.
5
6
Continuous or unvarying sadness, misery or despondency.
3
INNER TENSION—Representing feelings of ill-defined discomfort, edginess, inner 
turmoil, mental tension mounting to either panic, dread, or anguish. Rate according to 
intensity, frequency, duration, and the extent of reassurance called for.
0
Placid. Only fleeting inner tension.
1
2
Occasional feelings of edginess and ill-defined discomfort.
3
4
Continuous feelings of inner tension or intermittent panic which the patient can only 
master with some difficulty.
5
6
Unrelenting dread or anguish. Overwhelming panic.

Naurex, Inc
83
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
4. REDUCED SLEEP—Representing the experience of reduced duration or depth of sleep 
compared to the patient’s own normal pattern when well.
0
Sleeps as usual.
1
2
Slight difficulty dropping off to sleep or slightly reduced, light, or fitful sleep.
3
4
Sleep reduced or broken by at least 2 hours.
5
6
Less than 2or 3 hours sleep.
5. REDUCED APPETITE—Representing the feeling of a loss of appetite compared with 
when well. Rate by loss of desire for food or the need to force oneself to eat.
0
Normal or increased appetite.
1
2
Slightly reduced appetite.
3
4
No appetite. Food is tasteless.
5
6
Needs persuasion to eat at all.
6. CONCENTRATION DIFFICULTIES—Representing difficulties in collecting one’s 
thoughts mounting to incapacitating lack of concentration. Rate according to intensity, 
frequency, and degree of incapacity produced.
0
No difficulties in concentrating.
1
2
Occasional difficulties in collecting one’s thoughts.
3
4
Difficulties in concentrating and sustaining thought which reduces ability to read or hold 
a conversation.
5
6
Unable to read or converse without great difficulty.

Naurex, Inc
84
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
7. LASSITUDE—Representing a difficulty getting started or slowness initiating and 
performing everyday activities.
0
Hardly any difficulty getting started. No sluggishness.
1
2
Difficulties in starting activities.
3
4
Difficulties in starting simple routine activities which are carried out with effort.
5
6
Complete lassitude. Unable to do anything without help.
8. INABILITY TO FEEL—Representing the subjective experience of reduced interest in the 
surroundings, or activities that normally give pleasure. The ability to react with adequate 
emotion to circumstances or people is reduced.
0
Normal interest in the surroundings and in other people.
1
2
Reduced ability to enjoy usual interests.
3
4
Loss of interest in the surroundings. Loss of feelings for friends and acquaintances.
5
6
The experience of being emotionally paralyzed, inability to feel anger, grief or pleasure 
and a complete or even painful failure to feel for close relatives or friends.
9. PESSIMISTIC THOUGHTS—Representing thoughts of guilt, inferiority, self-reproach, 
sinfulness, remorse and ruin.
0
No pessimistic thoughts.
1
2
Fluctuating ideas of failure, self-reproach or self-deprecation.
3
4
Persistent self-accusations, or definite but still rational ideas of guilt or sin. Increasingly 
pessimistic about the future.
5
6
Delusions of ruin, remorse, or unredeemable sin. Self-accusations which are absurd and 
unshakable.

Naurex, Inc
85
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
10. SUICIDAL THOUGHTS—Representing the feeling that life is not worth living, that a 
natural death would be welcome, suicidal thoughts, and preparations for suicide. Suicidal 
attempts should not in themselves influence the rating.
0
Enjoys life or takes it as it comes.
1
2
Weary of life. Only fleeting suicidal thoughts.
3
4
Probably better off dead. Suicidal thoughts are common, and suicide is considered as a 
possible solution, but without specific plans or intention.
5
6
Explicit plans for suicide when there is an opportunity. Active preparations for suicide.

Naurex, Inc
86
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 
 
 
 
 
 
 
 

Naurex, Inc
87
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
88
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
89
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
90
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
91
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
92
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
93
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
94
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
95
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
96
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
97
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
 

Naurex, Inc
98
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
99
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
100
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
101
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
102
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
103
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
104
RAP-MD-01 Protocol Amendment 3
07 Dec 2018

Naurex, Inc
105
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
14.0
LITERATURE CITED
Abilify [package insert]. Tokyo, Japan; Otsuka Pharmaceutical Co., Ltd. December 2014.
American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders: 
DSM-5. Washington, DC: American Psychiatric Association
Ashton AK, Jamerson BD, Weinstein W, et al. Antidepressant-related adverse effects impacting 
treatment compliance: Results of a patient survey. Current Therapeutic Research, Clinical and 
Experimental 2005;66(2):
96-106.doi:10.1016/j.curtheres.2005.04.006.
Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive 
therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-
controlled study. J Clin Psychiatry 2007;68(6):843-53.
Boland RJ, Keller MB. Treatment of depression. In: Schatzberg AF, Nemeroff CB, editors. 
Essentials of clinical psychopharmacology. 2nd ed. Arlington, VA: American Psychiatric 
Publishing, Inc.; 2006. p 465-78.
Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the 
Clinician Administered Dissociative States Scale (CADSS). J Trauma Stress 1998;11:125–36.
EMA/CHMP/185423/2010 Rev. 2 previously (CPMP/EWP/518/97, Rev. 1) Committee for 
Medicinal Products for Human Use (CHMP) 30 May 2013 Guideline on clinical investigation of 
medicinal products in the treatment of depression
Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr 
Clin North Am. 1996 Jun;19(2):179-200.
FDA Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data 
Monitoring Committees, March 2006 
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf
FDA Guidance for Industry: Drug Induced Liver Injury- Pre-Marketing Clinical Evaluation, July 
2009
FDA Guidance for Industry: E10, Choice of Control Group and Related Issues in Clinical Trials, 
May 2001
Feifel D. The use of placebo-controlled clinical trials for the approval of psychiatric drugs: Part 
I—Statistics and the Case for the “Greater Good”. Psychiatry (Edgemont) 2008; 6(3)41–43
Gispen-de Wied C, Stoyanova V, Yu Y, et al. The placebo arm in clinical studies for treatment 
of Psychiatric Disorders: A Regulatory Dilemma. Eur Neuropsychopharmacol, 2012; 14 June 
(published ahead of print)

Naurex, Inc
106
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the 
United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64(12):1465-
75.
Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test battery, 
CNS Vital Signs. Arch Clin Neuropsychol. 2006 Oct;21(7):623-43.
Guy W: ECDEU Assessment Manual for Psychopharmacology - Revised, in (ed DHEW Publ No 
ADM 76-338). Rockville, MD, U.S., U.S. Department of Health, Education, and Welfare, Public 
Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH 
Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976, pp 
218-222
Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level 
version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20 (10):1727-36.
Kenward MG, Molenberghs G, Thijs H. Pattern-mixture models with proper time dependence. 
Biometrika 2003; 90(1): 53-71
Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum 
likelihood. Biometrics 1997; 53:983-97
Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of 
DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity 
Study. Arch Gen Psychiatry 1994;51:8-19.
Kessler RC, Chiu WJ, Demler O, et al. Prevalence, severity, and comorbidity of 
12-month DSM-IV disorders in the National Comorbidity Survey. Arch Gen Psychiatry 
2005;62(6): 617-27.
Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and 
schizophrenia: an FDA perspective. Eur Psychiatry. 2001; 16(7):418-23
Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as 
adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, 
placebo-controlled study. J Clin Psychopharmacol 2008;28(2):156-65.
Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 
2003;25(8):2289-304.
McIntyre RS and O’Donovan C. The human cost of not achieving full remission in depression. 
Can J Psychiatry 2004;49(suppl 1):10S-16S.
Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J 
Psychiatry 1979; 134:382-9
Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990-2010: burden of diseases, 
injuries, and risk factors. JAMA 2013;310(6):591-608.

Naurex, Inc
107
RAP-MD-01 Protocol Amendment 3
07 Dec 2018
Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and other NMDA antagonists: early 
clinical trials and possible mechanisms in depression. Am J Psychiatry 2015;172(10):950-66.
Overall JE and Gorham DR. The brief psychiatric rating scale. Psychological Reports 
1962;10:799-812.
Rapastinel: Investigator’s Brochure. Edition 7. Evanston, IL: Naurex, Inc; 01 Jul 2014. 
Rexulti [package insert]. Tokyo, Japan; Otsuka Pharmaceutical Co., Ltd. August 2015.
Rosenzweig-Lipson S, Beyer CG, Hughes ZA, et al. Differentiating antidepressants of the future: 
efficacy and safety. Pharmacol Ther 2007;113(1):134-53.
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed 
outpatients requiring one or several treatment steps: a STAR*D report. 
Am J Psychiatry 2006;163:1905-17.
Sachdev P. The epidemiology of drug-induced akathisia part II. Chronic, tardive, and withdrawal 
akathisias. Schizophren Bull 1995;21(3):451-61.
Seroquel [package insert]. Wilmington, DE; AstraZeneca Pharmaceuticals LP. October 2013.
Smith DW and Jones KL (1982). Recognizable Patterns of Human Malformation. (3 ed.) 
Philadelphia: Saunders.
Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentations after the failure of SSRIs 
for depression. N Engl J Med 2006;354(12):1243-52.
Videbech P and Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI 
studies. Am J Psychiatry 2004;161:1957-66.
World Health Organization. Mental health: new understanding, new hope. World Health Report 
2001

1
Naurex, Inc
RAP-MD-01 Protocol Amendment 3 Summary of Changes
07 Dec 2018
SUMMARY OF CHANGES TO PROTOCOL 
RAP-MD-01
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel 
as Adjunctive Therapy in Major Depressive Disorder
Amendment #3, 07 Dec 2018
IND # 107,974
Sponsor:
Naurex Inc., an indirect 
subsidiary of Allergan, plc
5 Giralda Farms
Madison, NJ 07940
Original Protocol Date:
28 Apr 2016
Amendment #1
28 Sep 2016
Amendment #2
12 Oct 2018
Confidentiality Statement
This document is the property of Allergan, plc and may not—in full or part—be passed 
on, reproduced, published, distributed, or submitted to any regulatory authority without 
the express written permission of Allergan, plc.

2
Naurex, Inc
RAP-MD-01 Protocol Amendment 3 Summary of Changes
07 Dec 2018
1.0
INTRODUCTION
Amendment #3 specifies the following changes to the RAP-MD-01 protocol amendment 
#2, dated 12 Oct 2018: 

Change in the sample size

Change in the statistical description of the determination of sample size

3
Naurex, Inc
RAP-MD-01 Protocol Amendment 3 Summary of Changes
07 Dec 2018
2.0
GLOBAL CHANGES
The following changes have been made globally to the protocol:

None.

4
Naurex, Inc
RAP-MD-01 Protocol Amendment 3 Summary of Changes
07 Dec 2018
3.0
SECTIONS DELETED
The following sections have been removed from the protocol:

None.

5
Naurex, Inc
RAP-MD-01 Protocol Amendment 3 Summary of Changes
07 Dec 2018
4.0
SECTIONS ADDED
The following sections have been added to the protocol:
None.

6
Naurex, Inc
RAP-MD-01 Protocol Amendment 3 Summary of Changes
07 Dec 2018
5.0
REVISIONS
The following revisions have been made to the protocol.
5.1
SECTION 9.1.2 DOUBLE-BLIND TREATMENT PERIOD
Rationale: This section has been amended to change the sample size.
This section has been amended as follows:
Approximately 360 460 patients are planned for enrollment in the double-blind treatment 
period (350 230 patients each in the rapastinel 450 mg and placebo groups). Patients will 
be randomized in a ratio of 1:1 to 1 of 2 treatment groups: rapastinel 450 mg IV weekly 
or placebo IV weekly (both adjunctive to ongoing ADT).
5.2
SECTION 9.7.9 DETERMINATION OF SAMPLE SIZE
Rationale: This section has been amended to reflect the results of the blinded interim 
analysis.
This section has been amended as follows:
The primary efficacy parameter is the change from Baseline to End of Study in
MADRS total score. The sample size estimation is based on the comparison of the 
primary efficacy endpoint between the rapastinel 450 mg and the placebo treatment 
groups. A sample size of 180 randomized patients in each group will provide 90% 
power to detect a treatment difference of 3.25 for the change from Baseline to End of 
Study based on an MMRM using simulations. The simulation assumed a pooled 
standard deviation of 8.7 for the change from Baseline to End of Study. This assumed 
pooled SD of 8.7 is supported by the blinded data review as described in Section 9.7.8 
(Interim Analysis): the pooled SDs were observed to be 7.4, 8.0, and 8.7 for Studies RAP-
MD-01, RAP-MD-02, and RAP-MD-03 respectively. The simulation also assumed a
correlation of 0.5 between the repeated measures and a common dropout rate of 
15% from Baseline to End of Study for all treatment groups. 
The originally proposed primary efficacy variable is the change from baseline in the 
MADRS total score at 1 day after the first dose of treatment. The study was planned to 
randomize 700 patients assuming standard deviation (SD) of 10 points, which provides 
99% power to detect a difference of 3.25 points in MADRS total score between rapastinel 
450 mg and placebo at a 2-sided significance level of 0.05.   
While the study was ongoing, the primary efficacy variable was revised to be the change 
from baseline in MADRS score at the last visit, Day 21, as recommended by the FDA, 
EMA, and PDMA, and included in Amendment 2 of the protocol. At the same time of 

7
Naurex, Inc
RAP-MD-01 Protocol Amendment 3 Summary of Changes
07 Dec 2018
Amendment 2, a blinded data review was conducted for Studies RAP-MD-01, RAP-MD-
02, and RAP-MD-03. The pooled SD for the 3 studies were 7.4, 8.0, and 8.7, 
respectively, all smaller than the originally assumed 10 points. Sample size was re-
calculated using 8.7 as the common SD. The calculation used MMRM model with 
simulations; it also assumed correlation of 0.5 between the repeated measures and an 
overall discontinuation rate of 15%. To have 90% power, the total sample size required is 
360 patients. However, the study had already enrolled more than 440 patients with less 
than 5% of overall discontinuation rate, surpassing the re-estimated sample size of 360 
patients. The study enrollment was halted as soon as operationally feasible. The final 
sample size is approximately 460 patients (230 patients per treatment group).